HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of VariZIG in pregnancy.

Abstract
Varicella infection during pregnancy is associated with serious maternal and fetal complications such as congenital varicella syndrome, maternal pneumonia and neonatal varicella. Pregnant women are ineligible to receive the varicella vaccination, thus women who lack evidence of immunity to varicella are at an increased risk for developing a varicella infection if exposed to a contagious individual. Presently, post-exposure prophylaxis involves the administration of a varicella zoster immunoglobulin (VariZIG™) to prevent or reduce the severity of an infection. The US FDA recently approved VariZIG for licensure and recommend that it be administered as soon as possible following VZV exposure, ideally within 96 h for greatest effectiveness. The following review critically examines the role of VariZIG in post-exposure prophylaxis of varicella during pregnancy.
AuthorsPriya Bapat, Gideon Koren
JournalExpert review of vaccines (Expert Rev Vaccines) Vol. 12 Issue 11 Pg. 1243-8 (Nov 2013) ISSN: 1744-8395 [Electronic] England
PMID24093779 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Immune Sera
  • varicella-zoster immune globulin
Topics
  • Chickenpox (prevention & control)
  • Drug Approval
  • Female
  • Humans
  • Immune Sera (administration & dosage)
  • Post-Exposure Prophylaxis (methods)
  • Pregnancy
  • Pregnancy Complications, Infectious (prevention & control)
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: